UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 30

Sortiert nach

Editorial: The relationship between COVID-19 severity and cancer immunity and immunotherapy

Frontiers in immunology, 2023-03, Vol.14, p.1184007-1184007

2023

Link zum Volltext

Verfügbarkeit prüfen

Human Papillomavirus and Survival of Sinonasal Squamous Cell Carcinoma Patients: A Systematic Review and Meta-Analysis

Cancers, 2021-07, Vol.13 (15), p.3677

2021

Link zum Volltext

Verfügbarkeit prüfen

How the Potassium Channel Response of T Lymphocytes to the Tumor Microenvironment Shapes Antitumor Immunity

Cancers, 2022-07, Vol.14 (15), p.3564

2022

Link zum Volltext

Verfügbarkeit prüfen

Genomic and Molecular Profiling of Human Papillomavirus Associated Head and Neck Squamous Cell Carcinoma Treated with Immune Checkpoint Blockade Compared to Survival Outcomes

Cancers, 2021-12, Vol.13 (24), p.6309

2021

Link zum Volltext

Verfügbarkeit prüfen

A Compartmentalized Reduction in Membrane-Proximal Calmodulin Reduces the Immune Surveillance Capabilities of CD8 + T Cells in Head and Neck Cancer

Frontiers in pharmacology, 2020-02, Vol.11, p.143-143

2020

Link zum Volltext

Verfügbarkeit prüfen

Immune Checkpoint Inhibitors Regulate K+ Channel Activity in Cytotoxic T Lymphocytes of Head and Neck Cancer Patients

Frontiers in pharmacology, 2021-08, Vol.12, p.742862-742862

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer

Cancers, 2022-05, Vol.14 (10), p.2355

2022

Link zum Volltext

Verfügbarkeit prüfen

Human papillomavirus induced transformation in cervical and head and neck cancers

Cancers, 2014-09, Vol.6 (3), p.1793-1820

2014

Link zum Volltext

Verfügbarkeit prüfen

Impact of p16 Status and Anatomical Site in Anti-PD-1 Immunotherapy-Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients

Cancers, 2021-09, Vol.13 (19), p.4861

2021

Link zum Volltext

Verfügbarkeit prüfen

Future directions and treatment strategies for head and neck squamous cell carcinomas

Translational research : the journal of laboratory and clinical medicine, 2012-09, Vol.160 (3), p.167-177

2012

Link zum Volltext

Verfügbarkeit prüfen

A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer

European journal of cancer (1990), 2013-07, Vol.49 (10), p.2345-2355

2013

Link zum Volltext

Verfügbarkeit prüfen

Oncolytic virotherapy for head and neck cancer: current research and future developments

Oncolytic virotherapy, 2015-01, Vol.4, p.83-93

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase II study evaluating the efficacy of niraparib and dostarlimab (TSR-042) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) patients

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.6046-6046

2023

Link zum Volltext

Verfügbarkeit prüfen

The genomic landscape and prognostic significance of 11.q.13 amplification in breast, head & neck, and lung cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e18037-e18037

2023

Link zum Volltext

Verfügbarkeit prüfen

TABLET: Relative bioavailability and bioequivalence study of niraparib tablets and capsules in patients with advanced solid tumors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e17603-e17603

2023

Link zum Volltext

Verfügbarkeit prüfen

Characterizing chromosome 3p/q genes as biomarkers of treatment response in squamous cell carcinoma of the lung and head and neck

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e18048-e18048

2023

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline

Journal of clinical oncology, 2023-02, Vol.41 (5), p.1132-1146

2023

Link zum Volltext

Verfügbarkeit prüfen

BXQ-350: Modulating ceramide and sphingosine-1-phosphate for antitumor activity in patients with advanced CRC

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.154-154

2023

Link zum Volltext

Verfügbarkeit prüfen

BXQ-350 may alleviate symptoms of chemotherapy- induced peripheral neuropathy via modulation of S1P

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.93-93

2023

Link zum Volltext

Verfügbarkeit prüfen

A phase 1, safety and dose escalation study of BXQ-350, a nanovesicle formulation of saposin c, a modulator of sphingolipid metabolism, in patients with advanced solid malignancies

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e15059-e15059

2022

Link zum Volltext

Verfügbarkeit prüfen

S1P/ceramides and cytokines as potential biomarkers of response following administration of bxq-350

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e15007-e15007

2022

Link zum Volltext

Verfügbarkeit prüfen

Initial efficacy and safety of RP1 + nivolumab in patients with anti–PD-1–failed melanoma from the ongoing phase 1/2 IGNYTE study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9509-9509

2023

Link zum Volltext

Verfügbarkeit prüfen

Updated results from the skin cancer cohorts from an ongoing phase 1/2 multicohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9553-9553

2022

Link zum Volltext

Verfügbarkeit prüfen

An update on the overall epidemiology, clinical characteristics, and outcomes from the COVID-19 and Cancer Consortium (CCC19)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.10565-10565

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 30

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(30)

Sprache

Englisch
(30)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(14)
Science & Technology
(14)
Oncology
(10)
Cancer
(6)
Human Papillomavirus
(6)
Tumors
(6)
Head And Neck Cancer
(5)
Immunotherapy
(5)
Squamous Cell Carcinoma
(5)
Biomarkers
(4)
Head & Neck Cancer
(4)
Humans
(4)
Medical Prognosis
(4)
Patients
(4)
Clinical Trials
(3)
Head And Neck Carcinoma
(3)
Head And Neck Squamous Cell Carcinoma
(3)
Ion Channels
(3)
Metastases
(3)
Metastasis
(3)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

IngentaConnect
(30)
EZB Electronic Journals Library
(28)
Journals@Ovid
(18)
NUS Single-Journal Subscriptions
(17)
MEDLINE
(4)
Elsevier ScienceDirect Journals Complete
(2)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(1)

2 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Editorial: The relationship between COVID-19 severity and cancer immunity and immunotherapy

Human Papillomavirus and Survival of Sinonasal Squamous Cell Carcinoma Patients: A Systematic Review and Meta-Analysis

How the Potassium Channel Response of T Lymphocytes to the Tumor Microenvironment Shapes Antitumor Immunity

Genomic and Molecular Profiling of Human Papillomavirus Associated Head and Neck Squamous Cell Carcinoma Treated with Immune Checkpoint Blockade Compared to Survival Outcomes

A Compartmentalized Reduction in Membrane-Proximal Calmodulin Reduces the Immune Surveillance Capabilities of CD8 + T Cells in Head and Neck Cancer

Immune Checkpoint Inhibitors Regulate K+ Channel Activity in Cytotoxic T Lymphocytes of Head and Neck Cancer Patients

Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer

Human papillomavirus induced transformation in cervical and head and neck cancers

Impact of p16 Status and Anatomical Site in Anti-PD-1 Immunotherapy-Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients

Future directions and treatment strategies for head and neck squamous cell carcinomas

A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer

Oncolytic virotherapy for head and neck cancer: current research and future developments

Phase II study evaluating the efficacy of niraparib and dostarlimab (TSR-042) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) patients

The genomic landscape and prognostic significance of 11.q.13 amplification in breast, head & neck, and lung cancer

TABLET: Relative bioavailability and bioequivalence study of niraparib tablets and capsules in patients with advanced solid tumors

Characterizing chromosome 3p/q genes as biomarkers of treatment response in squamous cell carcinoma of the lung and head and neck

Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline

BXQ-350: Modulating ceramide and sphingosine-1-phosphate for antitumor activity in patients with advanced CRC

BXQ-350 may alleviate symptoms of chemotherapy- induced peripheral neuropathy via modulation of S1P

A phase 1, safety and dose escalation study of BXQ-350, a nanovesicle formulation of saposin c, a modulator of sphingolipid metabolism, in patients with advanced solid malignancies

S1P/ceramides and cytokines as potential biomarkers of response following administration of bxq-350

Initial efficacy and safety of RP1 + nivolumab in patients with anti–PD-1–failed melanoma from the ongoing phase 1/2 IGNYTE study

Updated results from the skin cancer cohorts from an ongoing phase 1/2 multicohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE)

An update on the overall epidemiology, clinical characteristics, and outcomes from the COVID-19 and Cancer Consortium (CCC19)

Association of pathological response to neoadjuvant pembrolizumab with tumor PD-L1 expression and high disease-free survival (DFS) in patients with resectable, local-regionally advanced, head and neck squamous cell carcinoma (HNSCC)

Aktive Filter

Suchergebnisse filtern